The mutational landscape of adenoid cystic carcinoma.

腺样囊性癌的突变图谱

阅读:6
作者:Ho Allen S, Kannan Kasthuri, Roy David M, Morris Luc G T, Ganly Ian, Katabi Nora, Ramaswami Deepa, Walsh Logan A, Eng Stephanie, Huse Jason T, Zhang Jianan, Dolgalev Igor, Huberman Kety, Heguy Adriana, Viale Agnes, Drobnjak Marija, Leversha Margaret A, Rice Christine E, Singh Bhuvanesh, Iyer N Gopalakrishna, Leemans C Rene, Bloemena Elisabeth, Ferris Robert L, Seethala Raja R, Gross Benjamin E, Liang Yupu, Sinha Rileen, Peng Luke, Raphael Benjamin J, Turcan Sevin, Gong Yongxing, Schultz Nikolaus, Kim Seungwon, Chiosea Simion, Shah Jatin P, Sander Chris, Lee William, Chan Timothy A
Adenoid cystic carcinomas (ACCs) are among the most enigmatic of human malignancies. These aggressive salivary gland cancers frequently recur and metastasize despite definitive treatment, with no known effective chemotherapy regimen. Here we determined the ACC mutational landscape and report the exome or whole-genome sequences of 60 ACC tumor-normal pairs. These analyses identified a low exonic somatic mutation rate (0.31 non-silent events per megabase) and wide mutational diversity. Notably, we found mutations in genes encoding chromatin-state regulators, such as SMARCA2, CREBBP and KDM6A, suggesting that there is aberrant epigenetic regulation in ACC oncogenesis. Mutations in genes central to the DNA damage response and protein kinase A signaling also implicate these processes. We observed MYB-NFIB translocations and somatic mutations in MYB-associated genes, solidifying the role of these aberrations as critical events in ACC. Lastly, we identified recurrent mutations in the FGF-IGF-PI3K pathway (30% of tumors) that might represent new avenues for therapy. Collectively, our observations establish a molecular foundation for understanding and exploring new treatments for ACC.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。